{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T01:52:11Z","timestamp":1771379531558,"version":"3.50.1"},"reference-count":58,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2022,9,21]],"date-time":"2022-09-21T00:00:00Z","timestamp":1663718400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,9,21]],"date-time":"2022-09-21T00:00:00Z","timestamp":1663718400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Radiologie"],"published-print":{"date-parts":[[2022,11]]},"abstract":"<jats:title>Zusammenfassung<\/jats:title><jats:sec>\n                <jats:title>Hintergrund<\/jats:title>\n                <jats:p>Die in Deutschland angewandte Einteilung der Kardiomyopathien geht auf die Klassifikation der Europ\u00e4ischen Gesellschaft f\u00fcr Kardiologie (ESC) von 2008 zur\u00fcck. Dort werden sie nach ihrem Ph\u00e4notyp unterteilt, so dass die Magnetresonanztomographie (MRT) in der Lage ist, die unterschiedlichen Kardiomyopathien zu differenzieren.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Bildgebung und Differenzialdiagnostik<\/jats:title>\n                <jats:p>Die St\u00e4rke der MRT ist es, anhand der M\u00f6glichkeiten der Gewebsdifferenzierung nichtisch\u00e4mische Kardiomyopathien von anderen Erkrankungen mit \u00e4hnlichen morphofunktionellen Aspekten zu differenzieren. So gelingt im Fall der dilatativen Kardiomyopathie (DCM) eine Differenzierung zur inflammatorischen DCM. Im Fall der hypertrophen Kardiomyopathie (HCM) kann analog zur Echographie eine obstruktive und nichtobstruktive Form differenziert werden, aber auch die Detektion einer Amyloidose oder eines Morbus Fabry ist m\u00f6glich. Die Evaluation der rechtsventrikul\u00e4ren Funktion gelingt im Rahmen einer arrhythmogenen rechtsventrikul\u00e4ren Kardiomyopathie (ARVC) zuverl\u00e4ssig. Au\u00dferdem ist die MRT in der Lage, die charakteristische fettige Ersatzfibrose direkt nachzuweisen. Bei den seltenen restriktiven Kardiomyopathien kann sie die Restriktion nachvollziehen und z.\u202fB. mittels T1-, T2- und T2*-Mapping die Sphingolipid-Akkumulation im Myokard bei einem Morbus Fabry oder eine Eisen\u00fcberladung bei H\u00e4mochromatose nachvollziehen.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Innovationen<\/jats:title>\n                <jats:p>Die quantitativen Verfahren des parametrischen Mappings bieten die M\u00f6glichkeit eines Therapiemonitorings; die klinische Relevanz dieses Monitorings ist aber noch Gegenstand aktueller Forschung. Die unklassifizierten Kardiomyopathien k\u00f6nnen sich klinisch mit \u00e4hnlicher Symptomatik wie isch\u00e4mische oder inflammatorische Erkrankungen pr\u00e4sentieren, so dass im Fall eines Myokardinfarkts ohne verschlossene Koronararterien (\u201emyocardial infarction without obstructive coronary arteries\u201c, MINOCA) in der Herzkatheteruntersuchung die MRT ein entscheidendes diagnostisches Instrument ist, um die tats\u00e4chlich zugrundeliegende Erkrankung festzustellen. Gleicherma\u00dfen kann sie bei neuen Kardiomyopathien wie der Non-compaction-Kardiomyopathie der Wegbereiter f\u00fcr eine morphologische Krankheitsdefinition sein.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s00117-022-01068-6","type":"journal-article","created":{"date-parts":[[2022,9,21]],"date-time":"2022-09-21T12:03:48Z","timestamp":1663761828000},"page":"920-932","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Kardiale MRT bei nichtisch\u00e4mischen Kardiomyopathien","Cardiac MRI in nonischemic cardiomyopathies"],"prefix":"10.1007","volume":"62","author":[{"given":"Christian","family":"L\u00fccke","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthias","family":"Gutberlet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,9,21]]},"reference":[{"key":"1068_CR1","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1093\/eurheartj\/ehm342","volume":"29","author":"P Elliott","year":"2008","unstructured":"Elliott\u00a0P, Andersson\u00a0B, Arbustini\u00a0E et\u00a0al (2008) Classification of the cardiomyopathies: a\u00a0position statement from the European Society Of Cardiology Working Group on Myocardial and Pericardial Diseases. Eur Heart\u00a0J 29:270\u2013276","journal-title":"Eur Heart J"},{"key":"1068_CR2","doi-asserted-by":"publisher","first-page":"1807","DOI":"10.1161\/CIRCULATIONAHA.106.174287","volume":"113","author":"BJ Maron","year":"2006","unstructured":"Maron\u00a0BJ, Towbin\u00a0JA, Thiene\u00a0G et\u00a0al (2006) Contemporary definitions and classification of the cardiomyopathies: an American Heart Association Scientific Statement from the Council on Clinical Cardiology, Heart Failure and Transplantation Committee; Quality of Care and Outcomes Research and Functional Genomics and Translational Biology Interdisciplinary Working Groups; and Council on Epidemiology and Prevention. Circulation 113:1807\u20131816","journal-title":"Circulation"},{"key":"1068_CR3","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1136\/hrt.44.6.672","volume":"44","author":"WHO\/ISFC Task Force","year":"1980","unstructured":"WHO\/ISFC Task Force (1980) Report of the WHO\/ISFC task force on the definition and classification of cardiomyopathies. Br Heart\u00a0J 44:672\u2013673","journal-title":"Br Heart J"},{"key":"1068_CR4","doi-asserted-by":"publisher","first-page":"1180","DOI":"10.1016\/j.jcmg.2017.08.005","volume":"10","author":"AR Patel","year":"2017","unstructured":"Patel\u00a0AR, Kramer\u00a0CM (2017) Role of cardiac magnetic resonance in the diagnosis and prognosis of nonischemic cardiomyopathy. JACC Cardiovasc Imaging 10:1180\u20131193","journal-title":"JACC Cardiovasc Imaging"},{"key":"1068_CR5","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1161\/CIRCRESAHA.117.311059","volume":"121","author":"AJ Marian","year":"2017","unstructured":"Marian\u00a0AJ, Braunwald\u00a0E (2017) Hypertrophic cardiomyopathy: genetics, pathogenesis, clinical manifestations, diagnosis, and therapy. Circ Res 121:749\u2013770","journal-title":"Circ Res"},{"key":"1068_CR6","first-page":"100503","volume":"27","author":"M de Oliveira Antunes","year":"2020","unstructured":"de Oliveira Antunes\u00a0M, Scudeler\u00a0TL (2020) Hypertrophic cardiomyopathy. Int J Cardiol Heart Vasc 27:100503","journal-title":"Int J Cardiol Heart Vasc"},{"key":"1068_CR7","doi-asserted-by":"publisher","first-page":"75","DOI":"10.12659\/MSMBR.900437","volume":"22","author":"M Samak","year":"2016","unstructured":"Samak\u00a0M, Fatullayev\u00a0J, Sabashnikov\u00a0A et\u00a0al (2016) Cardiac hypertrophy: an introduction to molecular and cellular basis. Med Sci Monit Basic Res 22:75\u201379","journal-title":"Med Sci Monit Basic Res"},{"key":"1068_CR8","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1016\/j.jcmg.2012.11.013","volume":"6","author":"TD Karamitsos","year":"2013","unstructured":"Karamitsos\u00a0TD, Piechnik\u00a0SK, Banypersad\u00a0SM et\u00a0al (2013) Noncontrast T1 mapping for the diagnosis of cardiac amyloidosis. JACC Cardiovasc Imaging 6:488\u2013497","journal-title":"JACC Cardiovasc Imaging"},{"key":"1068_CR9","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.pcad.2019.11.009","volume":"63","author":"M Yildiz","year":"2020","unstructured":"Yildiz\u00a0M, Oktay\u00a0AA, Stewart\u00a0MH et\u00a0al (2020) Left ventricular hypertrophy and hypertension. Prog Cardiovasc Dis 63:10\u201321","journal-title":"Prog Cardiovasc Dis"},{"key":"1068_CR10","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1038\/s41598-017-00627-5","volume":"7","author":"L-M Wu","year":"2017","unstructured":"Wu\u00a0L\u2011M, Wu\u00a0R, Ou\u00a0Y\u2011R et al (2017) Fibrosis quantification in hypertensive heart disease with LVH and non-LVH: findings from T1 mapping and contrast-free cardiac diffusion-weighted imaging. Sci Rep 7:559","journal-title":"Sci Rep"},{"key":"1068_CR11","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1111\/joim.12324","volume":"277","author":"A Barison","year":"2015","unstructured":"Barison\u00a0A, Aquaro\u00a0GD, Pugliese\u00a0NR et\u00a0al (2015) Measurement of myocardial amyloid deposition in systemic amyloidosis: insights from cardiovascular magnetic resonance imaging. J\u00a0Intern Med 277:605\u2013614","journal-title":"J Intern Med"},{"key":"1068_CR12","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1016\/0002-9149(79)90388-6","volume":"44","author":"H Yamaguchi","year":"1979","unstructured":"Yamaguchi\u00a0H, Ishimura\u00a0T, Nishiyama\u00a0S et\u00a0al (1979) Hypertrophic nonobstructive cardiomyopathy with giant negative T waves (apical hypertrophy): ventriculographic and echocardiographic features in 30\u00a0patients. Am J Cardiol 44:401\u2013412","journal-title":"Am J Cardiol"},{"key":"1068_CR13","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1016\/j.jacc.2008.04.047","volume":"52","author":"I Olivotto","year":"2008","unstructured":"Olivotto\u00a0I, Maron\u00a0MS, Autore\u00a0C et\u00a0al (2008) Assessment and significance of left ventricular mass by cardiovascular magnetic resonance in hypertrophic cardiomyopathy. J\u00a0Am Coll Cardiol 52:559\u2013566","journal-title":"J Am Coll Cardiol"},{"key":"1068_CR14","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1016\/j.jcmg.2012.08.019","volume":"6","author":"VO Puntmann","year":"2013","unstructured":"Puntmann\u00a0VO, Voigt\u00a0T, Chen\u00a0Z et\u00a0al (2013) Native T1 mapping in differentiation of normal myocardium from diffuse disease in hypertrophic and dilated cardiomyopathy. JACC Cardiovasc Imaging 6:475\u2013484","journal-title":"JACC Cardiovasc Imaging"},{"key":"1068_CR15","doi-asserted-by":"publisher","first-page":"12","DOI":"10.2463\/mrms.mp.2017-0136","volume":"18","author":"F Yanagisawa","year":"2019","unstructured":"Yanagisawa\u00a0F, Amano\u00a0Y, Tachi\u00a0M et al (2019) Non-contrast-enhanced T1 mapping of dilated cardiomyopathy: comparison between native T1 values and late gadolinium enhancement. Magn Reson Med Sci 18:12\u201318","journal-title":"Magn Reson Med Sci"},{"key":"1068_CR16","doi-asserted-by":"publisher","first-page":"2490","DOI":"10.1161\/01.CIR.101.21.2490","volume":"101","author":"NM Ammash","year":"2000","unstructured":"Ammash\u00a0NM, Seward\u00a0JB, Bailey\u00a0KR et\u00a0al (2000) Clinical profile and outcome of idiopathic restrictive cardiomyopathy. Circulation 101:2490\u20132496","journal-title":"Circulation"},{"key":"1068_CR17","doi-asserted-by":"publisher","first-page":"1368","DOI":"10.1016\/j.jcmg.2019.07.015","volume":"13","author":"S Dorbala","year":"2020","unstructured":"Dorbala\u00a0S, Cuddy\u00a0S, Falk\u00a0RH (2020) How to image cardiac amyloidosis. JACC Cardiovasc Imaging 13:1368\u20131383","journal-title":"JACC Cardiovasc Imaging"},{"key":"1068_CR18","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1186\/s13550-018-0425-1","volume":"8","author":"L Baratto","year":"2018","unstructured":"Baratto\u00a0L, Park\u00a0SY, Hatami\u00a0N et al (2018) 18F-florbetaben whole-body PET\/MRI for evaluation of systemic amyloid deposition. EJNMMI Res 8:66","journal-title":"EJNMMI Res"},{"key":"1068_CR19","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.jcmg.2019.03.026","volume":"13","author":"A Baggiano","year":"2020","unstructured":"Baggiano\u00a0A, Boldrini\u00a0M, Martinez-Naharro\u00a0A et al (2020) Noncontrast magnetic resonance for the diagnosis of cardiac amyloidosis. JACC Cardiovasc Imaging 13:69\u201380","journal-title":"JACC Cardiovasc Imaging"},{"issue":"1","key":"1068_CR20","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1186\/s12872-018-0952-8","volume":"18","author":"P Kyriakou","year":"2018","unstructured":"Kyriakou\u00a0P, Mouselimis\u00a0D, Tsarouchas\u00a0A et\u00a0al (2018) Diagnosis of cardiac amyloidosis: a\u00a0systematic review on the role of imaging and biomarkers. BMC Cardiovasc Disord 18(1):221","journal-title":"BMC Cardiovasc Disord"},{"key":"1068_CR21","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1007\/s00392-015-0826-3","volume":"104","author":"F aus dem Siepen","year":"2015","unstructured":"aus dem Siepen\u00a0F, Buss\u00a0SJ, Andre\u00a0F et al (2015) Extracellular remodeling in patients with wild-type amyloidosis consuming epigallocatechin-3-gallate: preliminary results of T1 mapping by cardiac magnetic resonance imaging in a small single center study. Clin Res Cardiol 104:640\u2013647","journal-title":"Clin Res Cardiol"},{"key":"1068_CR22","doi-asserted-by":"publisher","first-page":"1299","DOI":"10.1016\/j.jcmg.2020.03.010","volume":"13","author":"JA Pan","year":"2020","unstructured":"Pan\u00a0JA, Kerwin\u00a0MJ, Salerno\u00a0M (2020) Native T1 mapping, extracellular volume mapping, and late gadolinium enhancement in cardiac amyloidosis. JACC Cardiovasc Imaging 13:1299\u20131310","journal-title":"JACC Cardiovasc Imaging"},{"key":"1068_CR23","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.radcr.2018.09.025","volume":"14","author":"S Oda","year":"2019","unstructured":"Oda\u00a0S, Kawano\u00a0Y, Okuno\u00a0Y et al (2019) Base-to-apex gradient pattern of cardiac impairment identified on myocardial T1 mapping in cardiac amyloidosis. Radiol Case Rep 14:72\u201374","journal-title":"Radiol Case Rep"},{"key":"1068_CR24","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1016\/j.jcct.2015.07.001","volume":"9","author":"TA Treibel","year":"2015","unstructured":"Treibel\u00a0TA, Bandula\u00a0S, Fontana\u00a0M et\u00a0al (2015) Extracellular volume quantification by dynamic equilibrium cardiac computed tomography in cardiac amyloidosis. J\u00a0Cardiovasc Comput Tomogr 9:585\u2013592","journal-title":"J Cardiovasc Comput Tomogr"},{"key":"1068_CR25","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1007\/s00392-015-0826-3","volume":"104","author":"F aus dem Siepen","year":"2015","unstructured":"aus dem Siepen\u00a0F, Buss\u00a0SJ, Andre\u00a0F et al (2015) Extracellular remodeling in patients with wild-type amyloidosis consuming epigallocatechin-3-gallate: preliminary results of T1 mapping by cardiac magnetic resonance imaging in a small single center study. Clin Res Cardiol 104:640\u2013647","journal-title":"Clin Res Cardiol"},{"key":"1068_CR26","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1002\/ehf2.12511","volume":"6","author":"J Brownrigg","year":"2019","unstructured":"Brownrigg\u00a0J, Lorenzini\u00a0M, Lumley\u00a0M et al (2019) Diagnostic performance of imaging investigations in detecting and differentiating cardiac amyloidosis: a\u00a0systematic review and meta-analysis. ESC Heart Fail 6:1041\u20131051","journal-title":"ESC Heart Fail"},{"key":"1068_CR27","doi-asserted-by":"publisher","first-page":"2712","DOI":"10.1016\/j.jacc.2016.09.953","volume":"68","author":"MG Trivieri","year":"2016","unstructured":"Trivieri\u00a0MG, Dweck\u00a0MR, Abgral\u00a0R et al (2016) 18F-sodium fluoride PET\/MR for the assessment of cardiac amyloidosis. J\u00a0Am Coll Cardiol 68:2712\u20132714","journal-title":"J Am Coll Cardiol"},{"key":"1068_CR28","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1001\/jama.2011.10","volume":"305","author":"MC Iannuzzi","year":"2011","unstructured":"Iannuzzi\u00a0MC, Fontana\u00a0JR (2011) Sarcoidosis: clinical presentation, immunopathogenesis, and therapeutics. JAMA 305:391\u2013399","journal-title":"JAMA"},{"key":"1068_CR29","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1055\/s-0030-1257126","volume":"66","author":"S Pabst","year":"2012","unstructured":"Pabst\u00a0S, Skowasch\u00a0D, Groh\u00e9\u00a0C (2012) Sarkoidose. Pneumologie 66:96\u2013109 (quiz 110)","journal-title":"Pneumologie"},{"key":"1068_CR30","first-page":"61","volume":"12","author":"A Pietinalho","year":"1995","unstructured":"Pietinalho\u00a0A, Hiraga\u00a0Y, Hosoda\u00a0Y et\u00a0al (1995) The frequency of sarcoidosis in Finland and Hokkaido, Japan. A comparative epidemiological study. Sarcoidosis 12:61\u201367","journal-title":"Sarcoidosis"},{"key":"1068_CR31","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1055\/s-2003-812420","volume":"57","author":"W Schulte","year":"2003","unstructured":"Schulte\u00a0W, Costabel\u00a0U, Kirsten\u00a0D (2003) Kardiale Sarkoidose. Pneumologie 57:752\u2013760","journal-title":"Pneumologie"},{"key":"1068_CR32","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.1007\/s12350-016-0658-1","volume":"25","author":"DR Okada","year":"2018","unstructured":"Okada\u00a0DR, Bravo\u00a0PE, Vita\u00a0T et al (2018) Isolated cardiac sarcoidosis: a focused review of an under-recognized entity. J\u00a0Nucl Cardiol 25:1136\u20131146","journal-title":"J Nucl Cardiol"},{"key":"1068_CR33","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1161\/CIRCULATIONAHA.114.011522","volume":"131","author":"R Kandolin","year":"2015","unstructured":"Kandolin\u00a0R, Lehtonen\u00a0J, Airaksinen\u00a0J et\u00a0al (2015) Cardiac sarcoidosis: epidemiology, characteristics, and outcome over 25\u00a0years in a\u00a0nationwide study. Circulation 131:624\u2013632","journal-title":"Circulation"},{"key":"1068_CR34","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1007\/s10741-019-09848-4","volume":"25","author":"AR Duraes","year":"2020","unstructured":"Duraes\u00a0AR, de Souza Lima Bitar\u00a0Y, Roever\u00a0L et\u00a0al (2020) Endomyocardial fibrosis: past, present, and future. Heart Fail Rev 25:725\u2013730","journal-title":"Heart Fail Rev"},{"key":"1068_CR35","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1016\/j.ijcard.2020.06.005","volume":"319","author":"D Corrado","year":"2020","unstructured":"Corrado\u00a0D, Perazzolo Marra\u00a0M, Zorzi\u00a0A et\u00a0al (2020) Diagnosis of arrhythmogenic cardiomyopathy: the Padua criteria. Int J Cardiol 319:106\u2013114","journal-title":"Int J Cardiol"},{"key":"1068_CR36","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1093\/eurheartj\/ehq025","volume":"31","author":"FI Marcus","year":"2010","unstructured":"Marcus\u00a0FI, McKenna\u00a0WJ, Sherrill\u00a0D et\u00a0al (2010) Diagnosis of arrhythmogenic right ventricular cardiomyopathy\/dysplasia: proposed modification of the task force criteria. Eur Heart\u00a0J 31:806\u2013814","journal-title":"Eur Heart J"},{"key":"1068_CR37","doi-asserted-by":"publisher","first-page":"2074","DOI":"10.1007\/s00330-010-1791-x","volume":"20","author":"C L\u00fccke","year":"2010","unstructured":"L\u00fccke\u00a0C, Schindler\u00a0K, Lehmkuhl\u00a0L et\u00a0al (2010) Prevalence and functional impact of lipomatous metaplasia in scar tissue following myocardial infarction evaluated by MRI. Eur Radiol 20:2074\u20132083","journal-title":"Eur Radiol"},{"key":"1068_CR38","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1007\/s00330-009-1549-5","volume":"20","author":"I Eitel","year":"2010","unstructured":"Eitel\u00a0I, L\u00fccke\u00a0C, Grothoff\u00a0M et\u00a0al (2010) Inflammation in takotsubo cardiomyopathy: insights from cardiovascular magnetic resonance imaging. Eur Radiol 20:422\u2013431","journal-title":"Eur Radiol"},{"key":"1068_CR39","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.jcmg.2017.01.025","volume":"11","author":"JA Lurz","year":"2018","unstructured":"Lurz\u00a0JA, Luecke\u00a0C, Lang\u00a0D et al (2018) CMR-derived extracellular volume fraction as a\u00a0marker for myocardial fibrosis: the importance of coexisting myocardial inflammation. JACC Cardiovasc Imaging 11:38\u201345","journal-title":"JACC Cardiovasc Imaging"},{"key":"1068_CR40","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1136\/heartjnl-2011-300960","volume":"98","author":"J Kuusisto","year":"2012","unstructured":"Kuusisto\u00a0J, K\u00e4rj\u00e4\u00a0V, Sipola\u00a0P et al (2012) Low-grade inflammation and the phenotypic expression of myocardial fibrosis in hypertrophic cardiomyopathy. Heart 98:1007\u20131013","journal-title":"Heart"},{"key":"1068_CR41","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1016\/S0140-6736(14)61282-4","volume":"386","author":"JA Towbin","year":"2015","unstructured":"Towbin\u00a0JA, Lorts\u00a0A, Jefferies\u00a0JL (2015) Left ventricular non-compaction cardiomyopathy. Lancet 386:813\u2013825","journal-title":"Lancet"},{"key":"1068_CR42","doi-asserted-by":"publisher","first-page":"e001908","DOI":"10.1136\/openhrt-2021-001908","volume":"9","author":"K Hirono","year":"2022","unstructured":"Hirono\u00a0K, Takarada\u00a0S, Miyao\u00a0N et al (2022) Thromboembolic events in left ventricular non-compaction: comparison between children and adults\u2014a\u00a0systematic review and meta-analysis. Open Heart 9:e1908","journal-title":"Open Heart"},{"key":"1068_CR43","doi-asserted-by":"publisher","first-page":"2699","DOI":"10.1007\/s00330-012-2554-7","volume":"22","author":"M Grothoff","year":"2012","unstructured":"Grothoff\u00a0M, Pachowsky\u00a0M, Hoffmann\u00a0J et al (2012) Value of cardiovascular MR in diagnosing left ventricular non-compaction cardiomyopathy and in discriminating between other cardiomyopathies. Eur Radiol 22:2699\u20132709","journal-title":"Eur Radiol"},{"key":"1068_CR44","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1038\/s41569-020-00435-x","volume":"18","author":"C Tsch\u00f6pe","year":"2021","unstructured":"Tsch\u00f6pe\u00a0C, Ammirati\u00a0E, Bozkurt\u00a0B et\u00a0al (2021) Myocarditis and inflammatory cardiomyopathy: current evidence and future directions. Nat Rev Cardiol 18:169\u2013193","journal-title":"Nat Rev Cardiol"},{"key":"1068_CR45","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1016\/j.jcmg.2013.10.011","volume":"7","author":"M Francone","year":"2014","unstructured":"Francone\u00a0M, Chimenti\u00a0C, Galea\u00a0N et al (2014) CMR sensitivity varies with clinical presentation and extent of cell necrosis in biopsy-proven acute myocarditis. JACC Cardiovasc Imaging 7:254\u2013263","journal-title":"JACC Cardiovasc Imaging"},{"key":"1068_CR46","doi-asserted-by":"publisher","first-page":"1326","DOI":"10.1093\/eurheartj\/ehm076","volume":"28","author":"ALP Caforio","year":"2007","unstructured":"Caforio\u00a0ALP, Calabrese\u00a0F, Angelini\u00a0A et al (2007) A prospective study of biopsy-proven myocarditis: prognostic relevance of clinical and aetiopathogenetic features at diagnosis. Eur Heart\u00a0J 28:1326\u20131333","journal-title":"Eur Heart J"},{"key":"1068_CR47","doi-asserted-by":"publisher","first-page":"1526","DOI":"10.1056\/NEJMra0800028","volume":"360","author":"LT Cooper","year":"2009","unstructured":"Cooper\u00a0LT (2009) Myocarditis. N\u00a0Engl J Med 360:1526\u20131538","journal-title":"N Engl J Med"},{"key":"1068_CR48","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1016\/j.amjcard.2021.07.009","volume":"157","author":"HM Salah","year":"2021","unstructured":"Salah\u00a0HM, Mehta\u00a0JL (2021) COVID-19 vaccine and myocarditis. Am J Cardiol 157:146\u2013148","journal-title":"Am J Cardiol"},{"key":"1068_CR49","doi-asserted-by":"publisher","first-page":"2636","DOI":"10.1093\/eurheartj\/eht210","volume":"34","author":"ALP Caforio","year":"2013","unstructured":"Caforio\u00a0ALP, Pankuweit\u00a0S, Arbustini\u00a0E et\u00a0al (2013) Current state of knowledge on aetiology, diagnosis, management, and therapy of myocarditis: a\u00a0position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases. Eur Heart\u00a0J 34:2636\u20132648 (2648a\u20132648d)","journal-title":"Eur Heart J"},{"key":"1068_CR50","doi-asserted-by":"publisher","first-page":"1802","DOI":"10.1161\/01.CIR.97.18.1802","volume":"97","author":"MG Friedrich","year":"1998","unstructured":"Friedrich\u00a0MG, Strohm\u00a0O, Schulz-Menger\u00a0J et al (1998) Contrast media-enhanced magnetic resonance imaging visualizes myocardial changes in the course of viral myocarditis. Circulation 97:1802\u20131809","journal-title":"Circulation"},{"key":"1068_CR51","doi-asserted-by":"publisher","first-page":"1475","DOI":"10.1016\/j.jacc.2009.02.007","volume":"53","author":"MG Friedrich","year":"2009","unstructured":"Friedrich\u00a0MG, Sechtem\u00a0U, Schulz-Menger\u00a0J et al (2009) Cardiovascular magnetic resonance in myocarditis: a JACC white paper. J\u00a0Am Coll Cardiol 53:1475\u20131487","journal-title":"J Am Coll Cardiol"},{"key":"1068_CR52","doi-asserted-by":"publisher","first-page":"1815","DOI":"10.1016\/j.jacc.2004.11.069","volume":"45","author":"H Abdel-Aty","year":"2005","unstructured":"Abdel-Aty\u00a0H, Boy\u00e9\u00a0P, Zagrosek\u00a0A et al (2005) Diagnostic performance of cardiovascular magnetic resonance in patients with suspected acute myocarditis: comparison of different approaches. J\u00a0Am Coll Cardiol 45:1815\u20131822","journal-title":"J Am Coll Cardiol"},{"key":"1068_CR53","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1056\/NEJM199508033330501","volume":"333","author":"JW Mason","year":"1995","unstructured":"Mason\u00a0JW, O\u2019Connell\u00a0JB, Herskowitz\u00a0A et\u00a0al (1995) A clinical trial of immunosuppressive therapy for myocarditis. The Myocarditis Treatment Trial Investigators. N\u00a0Engl J Med 333:269\u2013275","journal-title":"N Engl J Med"},{"key":"1068_CR54","doi-asserted-by":"publisher","first-page":"e190150","DOI":"10.1148\/ryct.2019190150","volume":"1","author":"M Gutberlet","year":"2019","unstructured":"Gutberlet\u00a0M, L\u00fccke\u00a0C (2019) Original versus 2018 Lake Louise criteria for acute myocarditis diagnosis: old versus new. Radiol Cardiothorac Imaging 1:e190150","journal-title":"Radiol Cardiothorac Imaging"},{"key":"1068_CR55","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1016\/j.jcmg.2014.02.005","volume":"7","author":"UK Radunski","year":"2014","unstructured":"Radunski\u00a0UK, Lund\u00a0GK, Stehning\u00a0C et\u00a0al (2014) CMR in patients with severe myocarditis: diagnostic value of quantitative tissue markers including extracellular volume imaging. JACC Cardiovasc Imaging 7:667\u2013675","journal-title":"JACC Cardiovasc Imaging"},{"issue":"8","key":"1068_CR56","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/j.jcmg.2014.07.026","volume":"2015","author":"JA Luetkens","year":"2015","unstructured":"Luetkens\u00a0JA, Doerner\u00a0J, Schild\u00a0H et\u00a0al (2015) Diagnostic value of quantitative CMR in patients suspected of having myocarditis: a\u00a0question of timing. JACC Cardiovasc Imaging 2015(8):109\u2013110. https:\/\/doi.org\/10.1016\/j.jcmg.2014.07.026","journal-title":"JACC Cardiovasc Imaging"},{"issue":"6","key":"1068_CR57","doi-asserted-by":"publisher","first-page":"e003073","DOI":"10.1161\/CIRCIMAGING.114.003073","volume":"8","author":"S Bohnen","year":"2015","unstructured":"Bohnen\u00a0S, Radunski\u00a0UK, Lund\u00a0GK et al (2015) Performance of t1 and t2 mapping cardiovascular magnetic resonance to detect active myocarditis in patients with recent-onset heart failure. Circ Cardiovasc Imaging 8(6):e3073","journal-title":"Circ Cardiovasc Imaging"},{"key":"1068_CR58","doi-asserted-by":"publisher","first-page":"1583","DOI":"10.1016\/j.jcmg.2017.12.008","volume":"11","author":"CP Kotanidis","year":"2018","unstructured":"Kotanidis\u00a0CP, Bazmpani\u00a0M\u2011A, Haidich\u00a0A\u2011B et al (2018) Diagnostic accuracy of cardiovascular magnetic resonance in acute myocarditis: a systematic review and meta-analysis. JACC Cardiovasc Imaging 11:1583\u20131590","journal-title":"JACC Cardiovasc Imaging"}],"container-title":["Die Radiologie"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00117-022-01068-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00117-022-01068-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00117-022-01068-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,30]],"date-time":"2022-10-30T06:02:46Z","timestamp":1667109766000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00117-022-01068-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,21]]},"references-count":58,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2022,11]]}},"alternative-id":["1068"],"URL":"https:\/\/doi.org\/10.1007\/s00117-022-01068-6","relation":{},"ISSN":["2731-7048","2731-7056"],"issn-type":[{"value":"2731-7048","type":"print"},{"value":"2731-7056","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,21]]},"assertion":[{"value":"18 August 2022","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 September 2022","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"C.\u00a0L\u00fccke: Tagungsleitung Deutsche Kardiodiagnostiktage, Vortr\u00e4ge f\u00fcr die Deutsche R\u00f6ntgengesellschaft und Deutsche Gesellschaft f\u00fcr An\u00e4sthesie, Cardiac Subcommitee Member ESR. M.\u00a0Gutberlet: Honorare erhalten f\u00fcr wissenschaftiche Vortr\u00e4ge und Fortbildungen von Bayer, Bracco, Circle CVI, Edwards, Philips, Siemens.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Potentielle Interessenkonflikte:"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autor\/-innen keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Potentielle Interessenkonflikte:"}}]}}